New study checks safety of combining two blood vessel drugs
NCT ID NCT07431294
First seen Mar 01, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-stage study looks at whether it is safe to take nitroglycerin spray together with a new drug called nurandociguat in people with stable coronary artery disease. Both drugs widen blood vessels, so combining them might cause a sudden drop in blood pressure. The study will monitor side effects and how the drugs interact in the body. About 36 adults aged 40 to 80 with stable CAD will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STABLE CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Comac Medical | Phase I Clinical Research Unit
Sofia, Sofia City Province, 1000, Bulgaria
-
Deutsches Herzzentrum der Charité (DHZC) - Klinik für Kardiologie, Angiologie und Intensivmedizin CVK
Berlin, 13353, Germany
-
SocraTec R&D Erfurt-Clinical Pharmacology Unit
Erfurt, 99084, Germany
-
UK Bonn Institut für Klinische Chemie und Klinische Pharmakologie, Phase I Einheit und Arzneimitteltherapiesicherheit
Bonn, 53127, Germany
-
Universitätsklinikum Heidelberg - Zentrum für Innere Medizin, Abteilung Klinische Pharmakologie und Pharmakoepidemologie
Heidelberg, 69120, Germany
Conditions
Explore the condition pages connected to this study.